- SIGA Technologies (NASDAQ:SIGA) says it reached concurrence with the FDA that no further clinical studies will be required for the IV formulation of TPOXX (tecovirimat) for the treatment of smallpox.
- The company anticipates filing the new drug application for the formulation in 2020.
- The FDA will not require additional efficacy data to support the NDA for the IV formulation.
- Source: Press Release
SIGA pushes ahead with smallpox treatment
Recommended For You
More Trending News
About SIGA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SIGA | - | - |
SIGA Technologies, Inc. |